Intimation under Regulation 30 - Rs. 517 Crores Global Sourcing Mandate
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.3 pts more than Nifty Microcap 250 and 5.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Welcure Drugs & Pharmaceuticals has secured a ₹517 crore global sourcing mandate from Fortune Sagar Impex Company Limited, Thailand. The mandate is fee-based — the company will earn a fixed 5% commission on the cost of goods sourced, translating into an estimated service income of about ₹25.85 crore to be recognised in FY 2025-26. Under the Ex-Works model, Welcure handles only sourcing and procurement of finished-dosage pharmaceutical SKUs, while the buyer is responsible for packaging, labelling, freight, insurance, and regulatory clearances in the destination country. Goods will be delivered in call-off tranches, with the first lot mobilised after prefunding milestones and the balance expected by 30 September 2026. The filing confirms this is not a related-party transaction.
This adds a meaningful chunk of fee-based revenue without putting extra burden on Welcure's balance sheet, but actual income recognition is thin (~5% margin) and contingent on call-offs being activated by the Thai client over the next ~15 months.